Zilovertamab (Synonyms: UC-961; Cirmtuzumab) |
Catalog No.GC66327
One-Click Copy Product Info
|
Zilovertamab is a humanized monoclonal antibody that inhibits the tumor promoting activity of the cancer stem cell antigen ROR1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2485779-13-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Zilovertamab is a humanized monoclonal antibody that inhibits the tumor promoting activity of the cancer stem cell antigen ROR1 [1]. Zilovertamab can inhibit ROR1-signaling and cancer-stemness gene expression in cancer cells, and impair metastases [2]. Zilovertamab has been widely used to inhibit the proliferation of various cancer cells and is employed in the development of combined therapies to effectively suppress tumor invasion[3].
In vitro, Zilovertamab (50μg/ml) treatment for 72 hours significantly inhibited the proliferation of CaOV3, CaOV3CisR and PEO1 cells[4]. Treatment with 20μg/ml Zilovertamab for 24 hours can inhibit the release of MMP-9 by chronic lymphocytic leukemia (CLL) cells promoted by Wnt5a[5]. Treatment with 10μg/ml Zilovertamab for 4 days can inhibit the proliferation of mantle cell lymphoma (MCL) cells promoted by Wnt5a and reduce the proportion of cells in the S/G2 phase[6].
In vivo, Zilovertamab treatment via daily intraperitoneal injection at a dose of 1mg/kg for 7 days significantly reduced the burden of leukemia cells in Rag2−/−γc−/− mice[7]. Zilovertamab (10mg/kg) was administered intravenously once every two weeks for a total of 6 weeks, which significantly inhibited the occurrence of lung metastasis in mice bearing breast cancer patient-derived xenografts (PDX) and markedly reduced the number of metastatic lesions[8].
References:
[1] Lee H J, Choi M Y, Siddiqi T, et al. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or marginal zone lymphoma (MZL)[J]. 2022.
[2] Shatsky R A, Batra-Sharma H, Helsten T, et al. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer[J]. Breast Cancer Research, 2024, 26(1): 32.
[3] Hasan M K, Widhopf II G F, Kipps T J. Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells[J]. Blood, 2023, 142: 6517.
[4] Liu D, Kaufmann G F, Breitmeyer J B, et al. The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells[J]. Pharmaceutics, 2022, 14(4): 837.
[5] Hasan M K, Widhopf II G F, Ghia E M, et al. Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia: CHRONIC LYMPHOCYTIC LEUKEMIA[J]. Leukemia, 2025, 39(7): 1661-1669.
[6] Yu J, Chen Y, Chen L, et al. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma[J]. Oncotarget, 2018, 9(37): 24731.
[7] Yu J, Chen L, Cui B, et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib[J]. Leukemia, 2017, 31(6): 1333-1339.
[8] Zhang S, Zhang H, Ghia E M, et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody[J]. Proceedings of the National Academy of Sciences, 2019, 116(4): 1370-1377.
| Cell experiment [1]: | |
Cell lines | CaOV3 cells |
Preparation Method | CaOV3 cells were cultivated in a 24-well plate at a density of 5×105 cells/ml in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 1% GlutaMAX and 1% penicillin/streptomycin. Cells were treated with Zilovertamab (50µg/ml) for 72h. The cell viability and ROR1 expression levels were determined. |
Reaction Conditions | 50µg/ml; 72h |
Applications | Zilovertamab treatment reduced the cell viability and downregulated ROR1 expression levels in CaOV3 cells. |
| Animal experiment [2]: | |
Animal models | Rag2−/−γc−/− mice |
Preparation Method | Rag2−/−γc−/− mice (4 weeks old) were maintained in a controlled environment at 22±3°C and 60% relative humidity under a 12h light/dark cycle, and were given free access to standard rodent nutrition and water. Breast cancer cells (1× 105, in phosphate buffered saline) were subcutaneously injected into the mammary pads of mice (5 mice per group). When tumors became palpable, the tumor-bearing mice were treated with Zilovertamab (10mg/kg) for 6 weeks (every two weeks; i.v.). Tumor size was measured every 4 days using a caliper, and tumor volume was calculated using the standard formula V=length×width2/2. |
Dosage form | 10mg/kg; every two weeks for 6 weeks; i.p. |
Applications | Zilovertamab treatment significantly inhibited tumor growth in mice bearing breast cancer cells. |
References: | |
| Cas No. | 2485779-13-1 | SDF | |
| Synonyms | UC-961; Cirmtuzumab | ||
| Formula | M.Wt | 144.57kDa | |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.9 μL | 34.6 μL | 69.2 μL |
| 5 mM | 1.4 μL | 6.9 μL | 13.8 μL |
| 10 mM | 0.7 μL | 3.5 μL | 6.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)